279 related articles for article (PubMed ID: 25914340)
1. Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials.
Kallel H; Kamen AA
Biotechnol J; 2015 May; 10(5):741-7. PubMed ID: 25914340
[TBL] [Abstract][Full Text] [Related]
2. Enhancing poxvirus vectors vaccine immunogenicity.
García-Arriaza J; Esteban M
Hum Vaccin Immunother; 2014; 10(8):2235-44. PubMed ID: 25424927
[TBL] [Abstract][Full Text] [Related]
3. Good manufacturing practice production of adenoviral vectors for clinical trials.
Lusky M
Hum Gene Ther; 2005 Mar; 16(3):281-91. PubMed ID: 15812223
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the development of adenovirus- and poxvirus-vectored tuberculosis vaccines.
Xing Z; Santosuosso M; McCormick S; Yang TC; Millar J; Hitt M; Wan Y; Bramson J; Vordermeier HM
Curr Gene Ther; 2005 Oct; 5(5):485-92. PubMed ID: 16250889
[TBL] [Abstract][Full Text] [Related]
5. Development and optimization of an adenovirus production process.
Kamen A; Henry O
J Gene Med; 2004 Feb; 6 Suppl 1():S184-92. PubMed ID: 14978761
[TBL] [Abstract][Full Text] [Related]
6. New viral vectors for infectious diseases and cancer.
Sasso E; D'Alise AM; Zambrano N; Scarselli E; Folgori A; Nicosia A
Semin Immunol; 2020 Aug; 50():101430. PubMed ID: 33262065
[TBL] [Abstract][Full Text] [Related]
7. Viral vectors for malaria vaccine development.
Li S; Locke E; Bruder J; Clarke D; Doolan DL; Havenga MJ; Hill AV; Liljestrom P; Monath TP; Naim HY; Ockenhouse C; Tang DC; Van Kampen KR; Viret JF; Zavala F; Dubovsky F
Vaccine; 2007 Mar; 25(14):2567-74. PubMed ID: 16914237
[TBL] [Abstract][Full Text] [Related]
8. A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever.
Sun Y; Li HY; Tian DY; Han QY; Zhang X; Li N; Qiu HJ
Vaccine; 2011 Oct; 29(46):8364-72. PubMed ID: 21888938
[TBL] [Abstract][Full Text] [Related]
9. Viral vectors in malaria vaccine development.
Limbach KJ; Richie TL
Parasite Immunol; 2009 Sep; 31(9):501-19. PubMed ID: 19691555
[TBL] [Abstract][Full Text] [Related]
10. Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.
Casimiro DR; Bett AJ; Fu TM; Davies ME; Tang A; Wilson KA; Chen M; Long R; McKelvey T; Chastain M; Gurunathan S; Tartaglia J; Emini EA; Shiver J
J Virol; 2004 Oct; 78(20):11434-8. PubMed ID: 15452269
[TBL] [Abstract][Full Text] [Related]
11. Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.
Conrad SJ; Liu J
Methods Mol Biol; 2019; 1937():189-209. PubMed ID: 30706397
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
13. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.
Capone S; D'Alise AM; Ammendola V; Colloca S; Cortese R; Nicosia A; Folgori A
Expert Rev Vaccines; 2013 Apr; 12(4):379-93. PubMed ID: 23560919
[TBL] [Abstract][Full Text] [Related]
14. Process optimization and scale-up for production of rabies vaccine live adenovirus vector (AdRG1.3).
Shen CF; Lanthier S; Jacob D; Montes J; Beath A; Beresford A; Kamen A
Vaccine; 2012 Jan; 30(2):300-6. PubMed ID: 22079076
[TBL] [Abstract][Full Text] [Related]
15. Pox viruses as eukaryotic cloning and expression vectors: future medical and veterinary vaccines.
Taylor J; Paoletti E
Prog Vet Microbiol Immunol; 1988; 4():197-217. PubMed ID: 3078866
[TBL] [Abstract][Full Text] [Related]
16. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.
Gómez CE; Nájera JL; Krupa M; Esteban M
Curr Gene Ther; 2008 Apr; 8(2):97-120. PubMed ID: 18393831
[TBL] [Abstract][Full Text] [Related]
17. Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.
Paoletti E; Taylor J; Meignier B; Meric C; Tartaglia J
Dev Biol Stand; 1995; 84():159-63. PubMed ID: 7796949
[TBL] [Abstract][Full Text] [Related]
18. Poxvirus vectors as HIV/AIDS vaccines in humans.
Gómez CE; Perdiguero B; Garcia-Arriaza J; Esteban M
Hum Vaccin Immunother; 2012 Sep; 8(9):1192-207. PubMed ID: 22906946
[TBL] [Abstract][Full Text] [Related]
19. Current Use of Adenovirus Vectors and Their Production Methods.
Sayedahmed EE; Kumari R; Mittal SK
Methods Mol Biol; 2019; 1937():155-175. PubMed ID: 30706395
[TBL] [Abstract][Full Text] [Related]
20. Challenges in manufacturing adenoviral vectors for global vaccine product deployment.
Vellinga J; Smith JP; Lipiec A; Majhen D; Lemckert A; van Ooij M; Ives P; Yallop C; Custers J; Havenga M
Hum Gene Ther; 2014 Apr; 25(4):318-27. PubMed ID: 24593243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
